VEXA Beauty™ announces the launch of the first fragrance line infused with oxytocin peptides, creating a new category at the intersection of beauty and wellness. This innovative collection features ...
In a recent achievement, DP Technology's hit discovery platform RiDYMO® has successfully designed a cyclic peptide targeting ?-catenin, a historically "undruggable" protein, in just two months. This ...
Dr. Yeilding received options to purchase 38,520 shares and restricted stock units (RSUs) to acquire 31,779 shares of Protagonist Therapeutics common stock. The exercise price of the options is $38.98 ...